PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Keytruda/Lenvima combo shows promise in hard-to-treat cancers

MSD (Merck) and Eisai have revealed new data from two trials under the LEAP clinical programme evaluating the combination of MSD’s PD-1 inhibitor Keytruda and Eisai’s oral tyrosine kinase inhibitor Lenvima.

The results, presented at the 2020 European Society for Medical Oncology (ESMO) virtual congress, showed that Keytruda (pembrolizumab) plus Lenvima (lenvatinib) demonstrated an objective response rate (ORR) of 21.4% in patients with unresectable or advance melanoma who had previously progressed on an anti-PD-1/L1 therapy.

In another phase II trial, Keytruda plus Lenvima demonstrated an ORR between 9.7-32.3% in previously treated patients with triple-negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer, glioblastoma multiforme (GBM) and biliary tract cancer (BTC).

However, the combo treatment performed better in certain cancers compared to others, reporting a response in 32.3% of highly-treated ovarian cancer patients and 29% of previously treated TNBC patients.

In third-line gastric cancer or second-line biliary tract cancer, the response rate was less impressive, with a 9.7% response rate recorded in each group. In addition, Keytruda plus Lenvima also produced a 16.1% response rate in the rare brain cancer glioblastoma multiforme (GBM).

“These new data from our LEAP clinical program show encouraging activity across several aggressive cancer types and expand our knowledge about the potential of KEYTRUDA plus LENVIMA to help a range of patients with these cancers,” said Scot Ebbinghaus, vice president, Clinical Research, Merck Research Laboratories.

“This is the first time that clinical data from two LEAP trials are being presented, reflecting important progress we are making to explore the potential of this combination for patients in need of new options, particularly those with advanced melanoma who have progressed on an anti-PD-1 or PD-L1 therapy,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026